![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Glioblastoma multiforme is the most malignant form of high-grade astrocytoma. Clinically it is characterized as 4th grade of astrocytoma having necrotic tissue and hyperplastic blood vessel. It is observed to be the most frequent adult brain tumor representing an overall 15.4% of all brain tumors and about 60-75% of the entire astrocytoma. There are limited therapies available, and the most widely used therapy includes surgical intrusion followed by radiotherapy plus chemotherapy (paclitaxel, temozolomide, docetaxel, etc.), with an overall patient survival rate from 6-14 months. Various studies have proved that nanoformulations offer considerable advantages like enhanced drug solubility, targeted activity, and attenuated side effects.
Objective: The key objective of this review article is to exemplify numerous studies carried out using nanocarriers for overcoming the challenges associated with the treatment of glioblastoma. It also describes the pathways associated with the induction, initiation, and progression of glioblastoma.
Methods: Research articles that focused on the use of nanocarrier-based drug delivery approach for the treatment of various glioblastoma were collected from different search engines such as Google Scholar, Science Direct, and PubMed using keywords like glioblastoma, nanocarriers, brain delivery, etc.
Results: Nanocarriers have shown enormous potential in overcoming the challenges associated with the treatment of glioblastoma.
Conclusion: Broad research is essential so that these nanocarriers can be used clinically for the welfare of mankind, in the management of glioblastoma, in the near future.
Keywords: Brain delivery, brain tumor, cancer, glioblastoma, nanocarrier, signalling pathway.
Current Pharmaceutical Design
Title:Overcoming the Challenges in the Treatment of Glioblastoma via Nanocarrier- based Drug Delivery Approach
Volume: 27 Issue: 45
Author(s): Saurabh Mittal, Javed Ali and Sanjula Baboota*
Affiliation:
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062,India
Keywords: Brain delivery, brain tumor, cancer, glioblastoma, nanocarrier, signalling pathway.
Abstract:
Background: Glioblastoma multiforme is the most malignant form of high-grade astrocytoma. Clinically it is characterized as 4th grade of astrocytoma having necrotic tissue and hyperplastic blood vessel. It is observed to be the most frequent adult brain tumor representing an overall 15.4% of all brain tumors and about 60-75% of the entire astrocytoma. There are limited therapies available, and the most widely used therapy includes surgical intrusion followed by radiotherapy plus chemotherapy (paclitaxel, temozolomide, docetaxel, etc.), with an overall patient survival rate from 6-14 months. Various studies have proved that nanoformulations offer considerable advantages like enhanced drug solubility, targeted activity, and attenuated side effects.
Objective: The key objective of this review article is to exemplify numerous studies carried out using nanocarriers for overcoming the challenges associated with the treatment of glioblastoma. It also describes the pathways associated with the induction, initiation, and progression of glioblastoma.
Methods: Research articles that focused on the use of nanocarrier-based drug delivery approach for the treatment of various glioblastoma were collected from different search engines such as Google Scholar, Science Direct, and PubMed using keywords like glioblastoma, nanocarriers, brain delivery, etc.
Results: Nanocarriers have shown enormous potential in overcoming the challenges associated with the treatment of glioblastoma.
Conclusion: Broad research is essential so that these nanocarriers can be used clinically for the welfare of mankind, in the management of glioblastoma, in the near future.
Export Options
About this article
Cite this article as:
Mittal Saurabh , Ali Javed and Baboota Sanjula *, Overcoming the Challenges in the Treatment of Glioblastoma via Nanocarrier- based Drug Delivery Approach, Current Pharmaceutical Design 2021; 27 (45) . https://dx.doi.org/10.2174/1381612827666210603152056
DOI https://dx.doi.org/10.2174/1381612827666210603152056 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential
Implications for Prognosis and Immunotherapy in Human Cancer
Combinatorial Chemistry & High Throughput Screening Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth
Anti-Cancer Agents in Medicinal Chemistry Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Translation of Circular RNAs: Functions of Translated Products and Related Bioinformatics Approaches
Current Bioinformatics TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Integrin α3 Mediates Stemness and Invasion of Glioblastoma by Regulating POU3F2
Current Protein & Peptide Science Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Preparation, Characterization and Drug Release of Salicylic Acid Loaded Porous Electrospun Nanofibers
Recent Patents on Nanotechnology Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine